Centrum Pulmonologii I Torakochirurgii W Bystrej
- Address
- lock Available on a paid plan
Advanced Non‑Small Cell Lung Cancer
Research at the Centrum Pulmonologii I Torakochirurgii W Bystrej focuses on targeted and immunotherapy approaches for patients with advanced non‑small cell lung cancer (NSCLC).
- HER2‑mutated NSCLC
- EGFR‑mutated NSCLC
- PD‑L1 expressing NSCLC
- KRAS‑G12C mutated NSCLC
Ongoing studies evaluate the efficacy and safety of novel antibody‑drug conjugates and combination regimens to improve survival outcomes.
Small‑Cell Lung Cancer
The department conducts trials aimed at improving outcomes for small‑cell lung cancer (SCLC) across both limited‑stage and extensive‑stage disease.
- First‑line chemo‑immunotherapy combinations
- Bispecific antibody therapies
- Comparative effectiveness versus standard topotecan
- Neoadjuvant approaches after chemoradiotherapy
These investigations seek to prolong overall survival and progression‑free survival while assessing safety in a high‑risk population.
Cancer Cachexia & Metabolic Support
A dedicated research line addresses cancer cachexia and related metabolic disturbances in lung‑cancer patients.
- GDF‑15 targeting agents
- Nutritional interventions combined with anti‑cachexia drugs
- Impact on body weight and quality of life
- Supportive care strategies for advanced disease
The goal is to improve functional status and overall well‑being alongside oncologic treatment.
Biomarker‑Driven Precision Oncology
Across multiple studies, the centre integrates biomarker‑driven precision oncology to match patients with the most appropriate targeted therapies.
- HER2 exon 19/20 mutations
- ALK rearrangements
- EGFR mutations
- PD‑L1 expression levels
Rapid molecular testing supports personalized treatment selection and accelerates access to innovative agents.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 1 of 2 therapeutic areas and 15 of 43 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 43 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1AstraZeneca AB3active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB6trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centrum Pulmonologii I Torakochirurgii W Bystrej
lock Showing 1 of 18 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Janssen Cilag International | Phase II | Recruiting | Dec 2025 | — |
IMP list
lock Showing 1 of 43 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 12 | Unknown | 2021-07-30 | 2025-10-28 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.